{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.93","upperLimit":"15.87","value":"13.37"},{"groupId":"OG001","lowerLimit":"8.74","upperLimit":"12.02","value":"10.58"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"441"},{"groupId":"OG001","value":"222"}],"units":"Participants"}],"description":"OS time was the elapsed time from the date of randomization to the date of death from any cause. OS was censored at the last date of contact for participants who were not known to have died as of the data-inclusion cut-off date for analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemetrexed: 500 mg/m\\^2, IV administration, q 21 days, until disease progression.\n\nBSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.","id":"OG000","title":"Pemetrexed and BSC"},{"description":"Placebo: IV administration, q 21 days.\n\nBSC: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.","id":"OG001","title":"Placebo and BSC"}],"paramType":"MEDIAN","populationDescription":"Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized. Participants censored: N = 138, 48 participants in the pemetrexed and placebo treatment arms, respectively.","reportingStatus":"POSTED","timeFrame":"Randomization to date of death from any cause (up to 41 months)","title":"Overall Survival (OS) Time","type":"SECONDARY","unitOfMeasure":"months"}